Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis
Transplantation and Cellular Therapy · 2026-10
DOI: 10.1016/j.jtct.2026.09.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2026-10. Verfasst von Marie Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota. Electronic address: hu000322@umn.edu. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences, Bristol-Myers Squibb Company, National Institutes of Health National Cancer Institute.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) commonly affects older patients >65 years old, with chimeric antigen receptor T-cell (CAR-T) therapy becoming an increasingly valuable treatment modality for relapsed/refractory (R/R) disease. Real world data on safety, efficacy, and management practices of CAR-T for older patients are important to inform clinical practice and referral. To compare efficacy and toxicities of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in younger (age 3) with no significant difference by age overall or within same CAR-T product. In total, 71 patients (38%) developed immune effector cell-associated neurotoxicity syndrome (ICANS) with 23% being grade ≥3. There was no difference in any grade ICANS between younger and older patients. On multivariate analysis, overall mortality was increased in patients with high IPI (HR 1.71, P 3) cytopenias at 3 months, and 100-day and 1-year non-relapse mortality (NRM) were also similar between younger and older patients. Data from our Cell Therapy Consortium retrospective analysis demonstrate that CAR-T recipients older than 65 yrs experience favorable outcomes and manageable toxicity similar to younger patients. Our results support the practice that age alone should not be a barrier to CAR-T consultation or therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota. Electronic address: hu000322@umn.edu.
- Masonic Cancer Center, University of Minnesota.
- University of Pennsylvania.
- MD Anderson Cancer Center.
- Memorial Sloan Kettering Cancer Center.
- David and Etta Jonas Center for Cellular Therapy, University of Chicago.
Förderung
- National Center for Advancing Translational Sciences
- Bristol-Myers Squibb Company
- National Institutes of Health National Cancer Institute
Zitieren
APA
Hu, M., Cao, Q., Porter, D. L., Schuster, S. J., Ahmed, S., Strati, P., Perales, M. A., Riedell, P. A., Bishop, M. R., McGuirk, J. P., Maziarz, R. T., Kungwankiattichai, S., Oluwole, O. O., & Bachanova, V. (2026). Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2026.09.014
Vancouver
Hu M, Cao Q, Porter DL, Schuster SJ, Ahmed S, Strati P, et al. Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis. Transplantation and Cellular Therapy. 2026. doi:10.1016/j.jtct.2026.09.014
BibTeX
@article{Hu2026,
author = {Hu, Marie and Cao, Qing and Porter, David L and Schuster, Stephen J and Ahmed, Sairah and Strati, Paolo and Perales, Miguel-Angel and Riedell, Peter A and Bishop, Michael R and McGuirk, Joseph P and Maziarz, Richard T and Kungwankiattichai, Smith and Oluwole, Olalekan O and Bachanova, Veronika},
title = {Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis},
journal = {Transplantation and Cellular Therapy},
year = {2026},
doi = {10.1016/j.jtct.2026.09.014}
}
EUVIMED